menu
    • menu
    [{"orgOrder":0,"company":"GondolaBio","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Demerger","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GondolaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GondolaBio \/ BridgeBio Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GondolaBio \/ BridgeBio Pharma"},{"orgOrder":0,"company":"GondolaBio","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||CIDEB","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"GondolaBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GondolaBio \/ GondolaBio","highestDevelopmentStatusID":"3","companyTruncated":"GondolaBio \/ GondolaBio"}]

    Find Clinical Drug Pipeline Developments & Deals by GondolaBio

    Menu

    GondolaBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GondolaBio

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            GondolaBio

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GondolaBio, n-Lorem Partner for ASO Therapies for Genetic Disease Advancement

                            Details : The collaboration aims to discover novel antisense oligonucleotide (ASO) medicines for patients who are not currently served by available treatment options.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GondolaBio

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            GondolaBio

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : BridgeBio Pharma

                            Deal Size : $300.0 million

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            BridgeBio launches another offshoot with $300M and early genetic disease programs

                            Details : GondolaBio will conduct R&D activities for early-stage clinical or preclinical programs across erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : BridgeBio Pharma

                            Deal Size : $300.0 million

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth